⮱Super-ARMS and ddPCR share the similar accuracy for EGFR mutation detection in plasma biopsy; both methods predicted well the efficacy of EGFR-TKIs by detecting plasma EGFR status.
⮱Translational Oncology (2018) 11, 542–545
⮱Detection of EGFR mutations in ctDNA is an effective method to identify patients who might beneft from frst-line geftinib treatment. Further analyses of dynamic alterations of EGFR mutations and accompanying gene aberrances could predict resistance to geftinib.
⮱www.thelancet.com/respiratory Published online July 12, 2018 http://dx.doi.org/10.1016/S2213-2600(18)30264-9
SuperARMS is a promising plasma-based assay for EGFR mutations, including T790M. It might be useful in advanced-stage lung adenocarcinoma patients whose tissue biopsy samples are insufficient for a traditional diagnostic EGFR assay or for patients with a poor performance status.
⮱Clinical Lung Cancer, 2017. https://doi.org/10.1016/j.cllc.2017.12.009
In conclusion, the results from this prospective study indicated the important clinical impact of T790 M detection using plasma samples for NSCLC patients who failed after EGFR-TKI therapy. Well concordance among three assays indicated the feasibility of plasma ctDNA detection. The ddPCR assay had a high sensitivity and might be superior to ARMS and SuperARMS assays.
⮱Pathol. Oncol. Res., 2017. DOI 10.1007/s12253-017-0286-3
ADx-SuperARMS EGFR assay is likely to be a highly sensitive and specific method to noninvasively detect plasma EGFR mutations of patients with advanced lung adenocarcinoma. The EGFR mutations detected by ADx-SuperARMS EGFR assay could predict the efficacy of the treatment with first generation of EGFR-TKIs. Hence, EGFR blood testing with ADxSuperARMS could address the unmet clinical needs.
⮱PLOS ONE, August 22, 2017. https://doi.org/10.1371/journal.pone.0183331.
⮱Histological tissues are preferred for anaplastic lymphoma kinase(ALK) fusion detection in non-small cell lung cancer(NSCLC). The aim of this study was to evaluate the feasibility of cytological sample as an alternative specimen for ALK fusion testing in patients with advanced NSCLC.
⮱LUNG CANCER, DOI: http://dx.doi.org/doi:10.1016/j.lungcan. 2016.01.014